Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2026-03-03 4:05 pm Purchase | 2026-02-24 | 13G | Zentalis Pharmaceuticals, Inc. ZNTL | Squadron Master Fund LP | 3,676,900 5.100% | 3,676,900 (New Position) | Filing History |
| 2026-02-17 12:36 pm Purchase | 2025-12-31 | 13G | Traws Pharma, Inc. TRAW | Squadron Master Fund LP | 713,540 8.900% | 122,540 (+20.73%) | Filing History |
| 2026-02-17 12:27 pm Unchanged | 2025-12-31 | 13G | Spruce Biosciences, Inc. SPRB | Squadron Master Fund LP | 70,000 6.500% | 0 (Unchanged) | Filing History |
| 2026-02-17 12:18 pm Purchase | 2025-12-31 | 13G | Relmada Therapeutics, Inc. RLMD | Squadron Master Fund LP | 7,395,510 9.900% | 4,097,010 (+124.21%) | Filing History |
| 2026-02-17 12:09 pm Sale | 2025-12-31 | 13G | Palisade Bio, Inc. PALI | Squadron Master Fund LP | 4,500,000 3.000% | -3,750,000 (-45.45%) | Filing History |
| 2026-02-17 12:00 pm Purchase | 2025-12-31 | 13G | NextCure, Inc. NXTC | Squadron Master Fund LP | 271,127 9.900% | 97,266 (+55.94%) | Filing History |
| 2026-02-17 11:49 am Purchase | 2025-12-31 | 13G | Lipocine Inc. LPCN | Squadron Master Fund LP | 530,000 9.500% | 30,000 (+6.00%) | Filing History |
| 2026-02-17 11:36 am Purchase | 2025-12-31 | 13G | Pasithea Therapeutics Corp. KTTA | Squadron Master Fund LP | 2,329,749 9.900% | 76,819 (+3.41%) | Filing History |
| 2025-12-23 3:49 pm Purchase | 2025-12-18 | 13G | Lipocine Inc. LPCN | Squadron Master Fund LP | 500,000 9.000% | 500,000 (New Position) | Filing History |
| 2025-12-05 4:10 pm Purchase | 2025-11-28 | 13G | Pasithea Therapeutics Corp. KTTA | Squadron Master Fund LP | 2,252,930 9.900% | 2,252,930 (New Position) | Filing History |
| 2025-11-14 2:29 pm Purchase | 2025-09-30 | 13G | Traws Pharma, Inc. TRAW | Squadron Master Fund LP | 591,000 8.400% | 170,499 (+40.55%) | Filing History |
| 2025-10-24 4:37 pm Purchase | 2025-10-21 | 13G | NextCure, Inc. NXTC | Squadron Master Fund LP | 173,861 6.500% | 173,861 (New Position) | Filing History |
| 2025-10-15 3:11 pm Purchase | 2025-10-08 | 13G | Spruce Biosciences, Inc. SPRB | Squadron Master Fund LP | 70,000 6.600% | 70,000 (New Position) | Filing History |
| 2025-10-08 4:12 pm Purchase | 2025-10-01 | 13G | Palisade Bio, Inc. PALI | Squadron Master Fund LP | 8,250,000 8.500% | 8,250,000 (New Position) | Filing History |
| 2025-09-19 3:04 pm Purchase | 2025-09-12 | 13G | Traws Pharma, Inc. TRAW | Squadron Master Fund LP | 420,501 6.000% | 420,501 (New Position) | Filing History |
| 2025-08-14 5:22 pm Purchase | 2025-06-30 | 13G | Relmada Therapeutics, Inc. RLMD | Squadron Master Fund LP | 3,298,500 9.900% | 1,248,500 (+60.90%) | Filing History |
| 2025-05-01 4:21 pm Purchase | 2025-04-24 | 13G | Relmada Therapeutics, Inc. RLMD | Squadron Master Fund LP | 2,050,000 6.200% | 2,050,000 (New Position) | Filing History |